# Fasting Bioequivalence Study of Memantinol 20 mg Tablets Versus Akatinol Memantine® 20 mg Tablets In Normal Healthy Subjects

> **NCT03121820** · PHASE1 · COMPLETED · sponsor: **Geropharm** · enrollment: 18 (actual)

## Conditions studied

- Bioequivalence, AUC, Cmax, Pharmacokinetics

## Interventions

- **DRUG:** Memantinol tablets, 20 mg
- **DRUG:** Akatinol Memantine® tablets, 20 mg

## Key facts

- **NCT ID:** NCT03121820
- **Lead sponsor:** Geropharm
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-11
- **Primary completion:** 2016-11-19
- **Final completion:** 2016-11-19
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2018-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03121820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03121820, "Fasting Bioequivalence Study of Memantinol 20 mg Tablets Versus Akatinol Memantine® 20 mg Tablets In Normal Healthy Subjects". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03121820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*